Celyad Oncology S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLYYF research report →
Companywww.celyad.com
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors.
- CEO
- Michel E. J. Lussier
- IPO
- 2014
- Employees
- 17
- HQ
- Mont-Saint-Guibert, BE
Price Chart
Valuation
- Market Cap
- $11.19M
- P/E
- 15.39
- P/S
- 637.32
- P/B
- 5.09
- EV/EBITDA
- -1.67
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 9195.24%
- Op Margin
- -34200.00%
- Net Margin
- 3833.33%
- ROE
- -242.11%
- ROIC
- -289.60%
Growth & Income
- Revenue
- $20.99K · -88.71%
- Net Income
- $829.69K · 114.25%
- EPS
- $0.02 · 113.86%
- Op Income
- $-7,179,309
- FCF YoY
- -21.43%
Performance & Tape
- 52W High
- $0.65
- 52W Low
- $0.15
- 50D MA
- $0.31
- 200D MA
- $0.27
- Beta
- 1.19
- Avg Volume
- 142
Get TickerSpark's AI analysis on CLYYF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CLYYF Coverage
We haven't published any research on CLYYF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CLYYF Report →